Product Images Rizatriptan Benzoate

The text describes a figure (Figure 1) that shows a Kaplan-Meier plot on the probability of achieving a headache response (no or mild pain) after treatment with rizatriptan benzoate or placebo. The plot displays the estimated probability of response over time, and the averages shown are based on pooled data from 4 placebo-controlled outpatient trials (Studies 1, 2, 3, and 4). The patients who took additional treatment or did not achieve headache response before 2 hours were not considered.*

This text provides a figure showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate Tablets or other medication for migraines over 24 hours following the initial dose of study treatment in pooled studies 1, 2, 3, and 4. The Kaplan-Meier plot is based on data obtained in four placebo-controlled outpatient clinical trials. Patients who did not use additional treatments were censored at 24 hours, and remedication was not allowed within two hours post-dose.*

The text describes the estimated probability of achieving an initial headache response with Rizatriptan Benzoate Orally Disintegrating Tablets by 2 hours in Pooled Studies 5 and 6. It shows a Kaptan-Meier graph of the probability of obtaining headache response with the medication or placebo over time. The text mentions that the displayed data is based on two placebo-controlled outpatient trials providing evidence of efficacy. Patients who did not achieve headache response within 2 hours were likely given additional treatment.*

This is a figure showing the Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Orally Disintegrating Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 5 and 6. The plot is a Kaplan-Mier plot based on data obtained in 2 placebo-controlled outpatient clinical trials (Studies 3 and 6). Patients not using additional treatments were censored at 24 hours. The plot includes both patients who had a headache response at 2 hours and those who had no response to the initial dose. However, some parts of the text are not readable due to errors.*

The image shows a graph titled "Figure 5" representing data obtained from "Study 7". It displays the percentage of patients who reported no headache pain 2 hours after taking a dose of either Rizatriptan Benzoate OD Tablets or placebo. The X-axis denotes the hours post Stage 2 dose, while the Y-axis denotes the percentage of patients. The text mentions specific percentages and markings on the graph related to both treatments.*

The text describes a medication package of orally disintegrating tablets called Rizatriptan Benzoate. The box contains 18 tablets divided into three blister cards, and each tablet is equivalent to 5 mg of Rizatriptan Benzoate. The package has a pharmacy label and was distributed by Rising Health, LLC. The text also contains some unreadable characters.*

This text appears to be a label of Rizatriptan Benzoate orally disintegrating tablets with instructions related to the contents of each tablet. It also mentions the ingredients and associated warning for users who have phenylketonuria. The label contains relevant information about the number of tablets and their distribution information.*